Predict your next investment

Venture Capital
synergylsp.com

See what CB Insights has to offer

Investments

25

Portfolio Exits

5

About Synergy Life Science Partners

Founded in 2006 by John Onopchenko, Richard Stack, M.D., and William Starling, Synergy Life Science Partners, LP, is a venture capital fund based in Portola Valley, CA that invests directly in private, early-stage medical device firms or emerging companies that are developing breakthrough, disruptive technologies to address unmet or underserved human healthcare needs.

Synergy Life Science Partners Headquarter Location

3284 Alpine Road

Portola Valley, California, 94028,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Synergy Life Science Partners News

OrbiMed leads $40 mln round for Inspire Medical Systems

May 15, 2014

May 15, 2014     0 Comments Inspire Medical Systems said Thursday that it has closed $40 million in Series E financing. OrbiMed led the round with participation from Johnson & Johnson Development Corp, Aperture Venture Partners, Kleiner Perkins Caufield & Byers, US Venture Partners, Synergy Life Science Partners, Medtronic, GDN Holdings and TGap Ventures. In addition to the funding, OrbiMed’s Chau Q. Khuong has been added to Inspire Medical Systems’ board of directors. Based in Minneapolis, Inspire Medical Systems is a maker of of an implanted device that treats a subset of patients with obstructive sleep apnea. PRESS RELEASE MINNEAPOLIS, May 15, 2014 /PRNewswire/ — Inspire Medical Systems, Inc. announced today that it has completed a Series E financing of $40 million. The financing round was strategically timed to coincide with the commercial launch of the Inspire® Upper Airway Stimulation (UAS) therapy in the United States. Last month, the FDA approved Inspire therapy , a first of its kind fully implanted device for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP) devices. Inspire therapy uses mild stimulation of the hypoglossal nerve to maintain an open airway during sleep. The financing was led by OrbiMed in New York. Other new investors in this round are the Johnson & Johnson Development Corporation and Aperture Venture Partners. Existing investors of Inspire Medical Systems also participated in the round, including Kleiner Perkins Caufield & Byers, US Venture Partners, Synergy Life Science Partners, Medtronic, GDN Holdings and TGap Ventures. OrbiMed Private Equity Partner, Chau Q. Khuong, will join the Inspire Medical Systems’ Board of Directors. “We are pleased to have the support and confidence of this esteemed group of investors,” said Tim Herbert, Inspire Medical Systems president and CEO. “This round of funding will enable Inspire Medical Systems to invest in the people and programs necessary to make this much–needed treatment available to patients and physicians.” “Inspire therapy fills an important and significant gap in the OSA treatment continuum,” said Chau Q. Khuong, OrbiMed private equity partner. “We believe that both physicians and patients will have great interest in this innovative new therapy.” As part of the growth strategy of the company, Inspire also today announced that Richard Buchholz has been appointed as the chief financial officer (CFO). Mr. Buchholz is a veteran medical device CFO most recently serving as CFO of superDimension, which was acquired in May 2012. He brings a broad experience base in both privately-held and public companies. Prior to joining superDimension, Mr. Buchholz served as CFO of Vascular Solutions. He started his career at Ernst & Young. Mr. Buchholz is a licensed certified public accountant and was named the 2012 CFO of the Year by the Minneapolis/St. Paul Business Journal. More than 18 million Americans have sleep apnea. Depending on the degree of severity, OSA can be a potentially life-threatening condition. Recent research shows that a person with poorly managed sleep apnea is at increased risk for heart attack, stroke, weight gain, high blood pressure and heart failure. Current treatments for OSA include weight loss, CPAP, oral appliances and anatomy altering surgeries. While these treatments are often successful, studies show that roughly half of all patients that start CPAP therapy, the current standard of care, eventually become non-compliant. Inspire therapy offers a proven treatment option for OSA patients who have not found relief from traditional treatment options. Inspire therapy is commercially available to patients at several centers in the United States, and additional U.S. clinical centers will have the therapy available in the second half of 2014. About Inspire therapy Inspire® Upper Airway Stimulation (UAS) is an FDA approved treatment for a subset of people with moderate to severe OSA who are unable to use CPAP. Inspire therapy is a fully implanted system, the first of its kind for sleep apnea, consisting of three components: a small generator, a sensing lead and a stimulation lead. The single external component, a small handheld Inspire sleep remote, is used to turn the therapy on before bed and off upon waking. When activated, Inspire therapy senses breathing patterns and delivers mild stimulation to key airway muscles, which keeps the airway open during sleep. Patients implanted with Inspire therapy who participated in the company’s STAR (Stimulation Therapy for Apnea Reduction) pivotal clinical trial experienced a 68 percent reduction in apnea events, a 70 percent reduction in oxygen desaturation events, and significant improvements in daytime functioning as measured by two validated questionnaires. These results were published in the January 9, 2014 issue of the New England Journal of Medicine. About Inspire Medical Systems Inspire Medical Systems, based in Minneapolis, Minn., was formed in 2007 when the technology and a significant intellectual property portfolio was spun-out of Medtronic MDT -0.94% . Inspire Medical Systems has developed the world’s first fully implanted and FDA approved neurostimulation system for the treatment of Obstructive Sleep Apnea (OSA). The Inspire system uses well-established neurostimulation technologies and incorporates a proprietary algorithm which stimulates key airway muscles based on a patient’s unique breathing patterns. Inspire therapy is designed to reduce OSA severity and improve quality of life for patients living with this challenging condition. Privately held, investors include Aperture Venture Partners, GDN Holdings, Johnson & Johnson Development Corporation, Kleiner Perkins Caufield & Byers, Medtronic, OrbiMed Advisors, Synergy Life Science Partners, TGap Ventures and US Venture Partners. Visit Inspire Medical Systems on the web at www.inspiresleep.com. About OrbiMed OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with approximately $11 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team of more than 80 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya. Related Posts

Synergy Life Science Partners Investments

25 Investments

Synergy Life Science Partners has made 25 investments. Their latest investment was in ShiraTronics as part of their Series A on October 10, 2019.

CBI Logo

Synergy Life Science Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/25/2019

Series A

ShiraTronics

$33M

Yes

7

4/18/2017

Series B

NeuroTronik

$23.1M

No

4

11/8/2016

Series F

Inspire Medical Systems

$37.5M

No

6

3/16/2015

Series E - II

Subscribe to see more

$99M

Subscribe to see more

10

5/15/2014

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/25/2019

4/18/2017

11/8/2016

3/16/2015

5/15/2014

Round

Series A

Series B

Series F

Series E - II

Series E

Company

ShiraTronics

NeuroTronik

Inspire Medical Systems

Subscribe to see more

Subscribe to see more

Amount

$33M

$23.1M

$37.5M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

4

6

10

10

Synergy Life Science Partners Portfolio Exits

5 Portfolio Exits

Synergy Life Science Partners has 5 portfolio exits. Their latest portfolio exit was Inspire Medical Systems on May 03, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/3/2018

IPO

$99M

3

10/20/2016

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/19/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

9/4/2013

Reverse Merger

Subscribe to see more

Subscribe to see more

10

7/3/2013

Acquired

Subscribe to see more

Subscribe to see more

0

Date

5/3/2018

10/20/2016

6/19/2015

9/4/2013

7/3/2013

Exit

IPO

IPO

Acquired

Reverse Merger

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

0

Synergy Life Science Partners Team

4 Team Members

Synergy Life Science Partners has 4 team members, including current Founder, Managing Director, William N. Starling.

Name

Work History

Title

Status

William N. Starling

Founder, Managing Director

Current

Tracy Pappas

Chief Financial Officer

Current

Mudit K. Jain

Managing Director

Current

Richard S. Stack

Managing Director

Current

Name

William N. Starling

Tracy Pappas

Mudit K. Jain

Richard S. Stack

Work History

Title

Founder, Managing Director

Chief Financial Officer

Managing Director

Managing Director

Status

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.